NAS:EPRX (Canada)
Â
Ordinary Shares
$
6.59
+0.19 (+2.96%)
10:08 PM EST
Business Description
Eupraxia Pharmaceuticals Inc
NAICS : 541710
SIC : 3741
ISIN : CA29842P1053
Share Class Description:
EPRX: Ordinary SharesTotal Employee Number:
49Description
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 69.19 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.04 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -1.7 | |||||
3-Year EPS without NRI Growth Rate | -3.1 | |||||
3-Year FCF Growth Rate | 0.8 | |||||
3-Year Book Growth Rate | 41.5 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.47 | |||||
9-Day RSI | 56.19 | |||||
14-Day RSI | 51.51 | |||||
3-1 Month Momentum % | 9.93 | |||||
6-1 Month Momentum % | -0.26 | |||||
12-1 Month Momentum % | 62.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 19.3 | |||||
Quick Ratio | 19.3 | |||||
Cash Ratio | 18.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -34 | |||||
Shareholder Yield % | -12.99 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -61.33 | |||||
ROA % | -58.78 | |||||
ROIC % | -3135.89 | |||||
3-Year ROIIC % | 74582.05 | |||||
ROC (Joel Greenblatt) % | -3616.52 | |||||
ROCE % | -67 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.91 | |||||
Price-to-Tangible-Book | 3.9 | |||||
EV-to-EBIT | -6.98 | |||||
EV-to-EBITDA | -7.02 | |||||
EV-to-Forward-Revenue | 2.17 | |||||
EV-to-FCF | -9.97 | |||||
| Price-to-Net-Current-Asset-Value | 4.02 | |||||
| Price-to-Net-Cash | 3.22 | |||||
Earnings Yield (Greenblatt) % | -14.33 | |||||
FCF Yield % | -7.5 |
GF Value™
Eupraxia Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eupraxia Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-04 | In 128 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 44 days | ||
| General meeting for 2025 | 2026-06-18 10:00 | 6.29 (+4.66%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 17:30 | 6.65 (-3.62%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 7.42 (+0.41%) | ||
| Guidance call for 2026 | 2026-04-21 11:00 | 7.20 (+2.27%) | ||
| Annual report for 2025 | 2026-03-12 | 7.69 (-3.51%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 7.69 (-3.51%) | ||
| Third quarter earnings results for 2025 | 2025-11-04 | 6.09 (+7.79%) | ||
| Second quarter earnings results for 2025 | 2025-08-12 | 5.33 (+1.24%) |
Show
Entries
Guru Commentaries on NAS:EPRX
No articles.
Press Release
Articles on Eupraxia Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers